MetaVia to Showcase DA-1726 Obesity Drug Data at EASL Congress 2026
Event summary
- MetaVia's late-breaking abstract on DA-1726 accepted for poster presentation at EASL Congress 2026, May 27–30 in Barcelona.
- DA-1726 is a novel GLP-1/glucagon dual agonist for obesity and MASH, administered once weekly subcutaneously.
- Phase 1 Part 3 titration study data on higher dose levels and tolerability expected in Q4 2026.
- Pre-clinical studies show DA-1726 achieved superior weight loss compared to semaglutide and similar reduction to tirzepatide and survodutide while preserving lean body mass.
- MetaVia also developing vanoglipel (DA-1241) for MASH treatment.
The big picture
MetaVia's presentation at EASL Congress 2026 underscores the growing competition in the obesity and MASH drug markets, where GLP-1/glucagon dual agonists are emerging as a key innovation. The company's focus on differentiated profiles like DA-1726's potential for superior weight loss and lipid-lowering effects highlights the strategic shift towards more comprehensive cardiometabolic treatments. With Phase 1 data on higher doses expected later this year, MetaVia's ability to execute on its clinical strategy will be critical in maintaining its competitive edge.
What we're watching
- Clinical Efficacy
- Whether DA-1726 can sustain its best-in-class weight loss and glucose control profile in higher dose Phase 1 trials.
- Regulatory Pathway
- The pace at which MetaVia advances DA-1726 through clinical stages given the competitive obesity drug landscape.
- Market Differentiation
- How DA-1726's unique mechanism and lean body mass preservation will position it against established GLP-1 agonists.
Related topics